Comparison of Depression in Hemodialysis, Peritoneal Dialysis, and Kidney Transplant Patients: A Systematic Review with Meta-Analysis.

IF 3 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES
Gloria M Zaragoza-Fernández, José C De La Flor, Verónica Fernández Abreu, Elisa Iglesias Castellano, Laura Rodríguez-Barbero Requena, Rafael Fernández Castillo
{"title":"Comparison of Depression in Hemodialysis, Peritoneal Dialysis, and Kidney Transplant Patients: A Systematic Review with Meta-Analysis.","authors":"Gloria M Zaragoza-Fernández, José C De La Flor, Verónica Fernández Abreu, Elisa Iglesias Castellano, Laura Rodríguez-Barbero Requena, Rafael Fernández Castillo","doi":"10.3390/jpm15050179","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Depression is a common comorbidity in patients with chronic kidney disease undergoing renal replacement therapy. This meta-analysis compares depression prevalence across hemodialysis, peritoneal dialysis, and kidney transplantation, considering mean age, treatment duration, comorbidities (diabetes and hypertension), and measurement instruments. <b>Methods:</b> A systematic review and meta-analysis of 16 studies involving 26,301 participants was conducted in accordance with PRISMA guidelines and registered in PROSPERO. It analyzed observational studies (2000-2024) on depression in patients receiving hemodialysis, peritoneal dialysis, or kidney transplantation. Data extraction included sample size, mean age, treatment duration, comorbidities, and measurement instruments. Random-effects models calculated the standardized mean differences and pooled prevalence estimates. Heterogeneity (Cochran's Q, I<sup>2</sup>) and publication bias (Egger's test) were assessed. <b>Results:</b> Depression prevalence was 35.56% (95% CI: 34.2-37.0%) in hemodialysis, 35.09% (95% CI: 33.5-36.7%) in peritoneal dialysis, and 25.33% (95% CI: 24.0-26.6%) in kidney transplant recipients. No significant differences were found between hemodialysis and peritoneal dialysis. Mean age, treatment duration, comorbidities, and measurement instruments were not significantly associated with depression prevalence. <b>Conclusions:</b> Kidney transplantation is linked to a lower depression prevalence than dialysis, while no significant differences exist between hemodialysis and peritoneal dialysis. These findings highlight the need to ensure timely transplantation access and enhance psychological support for dialysis patients. Further research should explore psychosocial factors and targeted interventions to improve mental health in this population.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 5","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12113119/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jpm15050179","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Depression is a common comorbidity in patients with chronic kidney disease undergoing renal replacement therapy. This meta-analysis compares depression prevalence across hemodialysis, peritoneal dialysis, and kidney transplantation, considering mean age, treatment duration, comorbidities (diabetes and hypertension), and measurement instruments. Methods: A systematic review and meta-analysis of 16 studies involving 26,301 participants was conducted in accordance with PRISMA guidelines and registered in PROSPERO. It analyzed observational studies (2000-2024) on depression in patients receiving hemodialysis, peritoneal dialysis, or kidney transplantation. Data extraction included sample size, mean age, treatment duration, comorbidities, and measurement instruments. Random-effects models calculated the standardized mean differences and pooled prevalence estimates. Heterogeneity (Cochran's Q, I2) and publication bias (Egger's test) were assessed. Results: Depression prevalence was 35.56% (95% CI: 34.2-37.0%) in hemodialysis, 35.09% (95% CI: 33.5-36.7%) in peritoneal dialysis, and 25.33% (95% CI: 24.0-26.6%) in kidney transplant recipients. No significant differences were found between hemodialysis and peritoneal dialysis. Mean age, treatment duration, comorbidities, and measurement instruments were not significantly associated with depression prevalence. Conclusions: Kidney transplantation is linked to a lower depression prevalence than dialysis, while no significant differences exist between hemodialysis and peritoneal dialysis. These findings highlight the need to ensure timely transplantation access and enhance psychological support for dialysis patients. Further research should explore psychosocial factors and targeted interventions to improve mental health in this population.

血液透析、腹膜透析和肾移植患者抑郁的比较:一项荟萃分析的系统回顾。
背景:抑郁症是接受肾脏替代治疗的慢性肾脏疾病患者的常见合并症。本荟萃分析比较了血液透析、腹膜透析和肾移植患者的抑郁患病率,考虑了平均年龄、治疗持续时间、合并症(糖尿病和高血压)和测量仪器。方法:根据PRISMA指南并在PROSPERO注册,对16项涉及26,301名参与者的研究进行了系统回顾和荟萃分析。该研究分析了2000-2024年接受血液透析、腹膜透析或肾移植患者抑郁的观察性研究。数据提取包括样本量、平均年龄、治疗持续时间、合并症和测量仪器。随机效应模型计算了标准化的平均差异和汇总的患病率估计。评估异质性(Cochran’s Q, I2)和发表偏倚(Egger’s检验)。结果:血液透析组抑郁患病率为35.56% (95% CI: 34.2-37.0%),腹膜透析组为35.09% (95% CI: 33.5-36.7%),肾移植组为25.33% (95% CI: 24.0-26.6%)。血液透析与腹膜透析无显著差异。平均年龄、治疗时间、合并症和测量工具与抑郁症患病率无显著相关性。结论:与透析相比,肾移植与抑郁症患病率较低有关,而血液透析与腹膜透析之间没有显著差异。这些发现强调了确保及时移植和加强透析患者心理支持的必要性。进一步的研究应探索社会心理因素和有针对性的干预措施,以改善这一人群的心理健康。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Personalized Medicine
Journal of Personalized Medicine Medicine-Medicine (miscellaneous)
CiteScore
4.10
自引率
0.00%
发文量
1878
审稿时长
11 weeks
期刊介绍: Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., pharmacogenomics/proteomics, systems biology). JPM recognizes that personalized medicine—the assessment of genetic, environmental and host factors that cause variability of individuals—is a challenging, transdisciplinary topic that requires discussions from a range of experts. For a comprehensive perspective of personalized medicine, JPM aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects. We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信